Status:
COMPLETED
Using Smokeless Tobacco Products With Lower Nicotine Levels to Reduce Negative Effects of Smokeless Tobacco Use
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Tobacco Use Disorder
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Though spit tobacco is smokeless, it still affects the cardiovascular system and may be associated with heart disease, stroke, and high blood pressure. This study will assess the effectiveness of limi...
Detailed Description
Spit tobacco presents as many health risks to its users as smoking tobacco. It affects the cardiovascular system and may be associated with heart disease, stroke, and high blood pressure. Long-term ef...
Eligibility Criteria
Inclusion
- Not interested in quitting ST use within 90 days of study entry
- Has been using ST at least six times a day for 6 months prior to study entry
- Agrees to use an effective form of contraception throughout the study
Exclusion
- Current use of other tobacco or nicotine products
- Pregnant or breastfeeding
- Any unstable medical condition
- Use of any medication that may affect tobacco use or be affected by reduction of tobacco use
- DSM-IV diagnosis of any psychiatric disorders or substance abuse disorders within 6 months prior to study entry
- Use of any psychotropic medications within 6 months prior to study entry
Key Trial Info
Start Date :
August 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00218244
Start Date
August 1 2001
End Date
November 1 2004
Last Update
January 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455